Insights

Type Clear all

Select all that apply

Topic Clear all

Select all that apply

icons/content-types/video webinar

The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...

icons/content-types/video webinar

Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...

icons/content-types/article article

Parenteral formulations are broadly characterized as sterile solutions, suspensions, emulsions, and powders for reconstitution for injection or infusion; they are administered directly to subjects, entering the systemic circulation and typically prov...

icons/content-types/fact sheet fact sheet

If you’re involved in late drug discovery, API manufacture, drug product formulation, clinical material production, or manufacture of final dosage form, a basic understanding and awareness of solid form issues could save you a great deal of difficu...

icons/content-types/fact sheet fact sheet

The term amorphous is used loosely in the pharmaceutical industry. A strict definition would limit amorphous to those materials which truly have no long range order, only the short range order characteristic of liquids. However, the term is popular...

icons/content-types/fact sheet fact sheet

It is important to have both a clear, science-based understanding of how the amorphous active drug is formed and also a comprehensive characterization of its fundamental properties, such as Tg, water vapor sorption, and relaxation time as a function...

icons/content-types/article article

Two isomers of Mogroside VI, Mogroside VIa1 (1) and Mogroside VIa (2), were isolated from the extracts of Luo Han Guo. Compound 1 is a newly isolated isomer of Mogroside VI. We report here detailed structural confirmation of the structures of 1 and 2...

icons/content-types/infographic infographic

Curia has remained on the cutting-edge of package testing technology with state-of-the-art programs for assessing package system integrity. Within the pharmaceutical industry Container Closure Integrity Testing (CCIT) is crucial in ensuring safety an...

icons/content-types/article article

Demands to rapidly advance drugs while minimizing cost as well as maintaining sterility assurance and high safety standards are accelerating the pace of change across the fill/finish industry.  As medicines shift from one-size-fits-all treatments to...

icons/content-types/fact sheet fact sheet

Curia provides cGMP dissolution support for APIs and a wide variety of dosage forms in various buffered, biorelevant, and mixed organic-phase media.  We have capability with various USP dissolution apparatus, including multi scale and automated rota...

icons/content-types/article article

From target discovery through launching a finished product to market, developing a new drug is a complex process which takes on average 10-15 years and costs around 2.6 billion dollars. Early on, this process often involves a high-throughput screenin...

icons/content-types/article article

With increasing antibiotic resistance observed amongst clinical isolates of Neisseria gonorrhoeae, the second most prevalent sexually transmitted bacterial disease in the United States, there is still a need for antimicrobial susceptibility testing...